{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02181478",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CASE1Z14"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "NCI-2014-01316",
            "SecondaryIdType": "Registry Identifier",
            "SecondaryIdDomain": "CTRP (Clinical Trial Reporting Program)"
          },
          {
            "SecondaryId": "CASE1Z14",
            "SecondaryIdType": "Other Identifier",
            "SecondaryIdDomain": "Case Comprehensive Cancer Center"
          },
          {
            "SecondaryId": "P30CA043703",
            "SecondaryIdType": "U.S. NIH Grant/Contract",
            "SecondaryIdLink": "https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=P30CA043703&Fy=all"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Case Comprehensive Cancer Center",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Intra-Osseous Co-Transplant of UCB and hMSC",
      "OfficialTitle": "Intra-osseous Co-transplant of Cord Blood and Mesenchymal Stromal Cells: A Feasibility Study"
    },
    "StatusModule": {
      "StatusVerifiedDate": "December 2020",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "July 22, 2015",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 19, 2019",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "February 7, 2020",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "July 2, 2014",
      "StudyFirstSubmitQCDate": "July 3, 2014",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "July 4, 2014",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "December 3, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "December 4, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Marcos de Lima",
        "ResponsiblePartyInvestigatorTitle": "Principal Investigator",
        "ResponsiblePartyInvestigatorAffiliation": "Case Comprehensive Cancer Center"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Case Comprehensive Cancer Center",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "National Cancer Institute (NCI)",
            "CollaboratorClass": "NIH"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This clinical trial studies intra-osseous donor umbilical cord blood and mesenchymal stromal cell co-transplant in treating patients with hematologic malignancies. Giving low doses of chemotherapy and total-body irradiation before a co-transplant of donor umbilical cord blood and mesenchymal stromal cells into the bone (intra-osseous) helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil at the time of transplant may stop this from happening.",
      "DetailedDescription": "PRIMARY OBJECTIVES:\n\nI. To estimate the feasibility of combining intra-osseous umbilical cord blood (UCB) hematopoietic stem cells and human mesenchymal stromal cells (hMSC) following reduced intensity conditioning (RIC).\n\nSECONDARY OBJECTIVES:\n\nI. To estimate the time to engraftment of intra-osseous (IO) UCB transplant combined with hMSC following RIC.\n\nII. To estimate the safety profile of IO UBC transplant combined with hMSC.\n\nOUTLINE:\n\nREDUCED INTENSITY CONDITIONING: Patients receive cyclophosphamide intravenously (IV) over 2 hours on day -6 and fludarabine phosphate IV on days -6 to -2 and undergo total body irradiation (TBI) on day -1.\n\nGRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS: Patients receive cyclosporine orally (PO) or IV over 2 hours every 12 hours on beginning on days -5 to 100 with taper beginning on day 100 and mycophenolate mofetil IV or PO twice daily (BID) on days -5 to 100.\n\nTRANSPLANT: Patients undergo intra-osseous UCB and hMSC co-transplant on day 0.\n\nAfter completion of study treatment, patients are followed up at days 28 and 100, and then at 6, 9, and 12 months."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Acute Lymphoblastic Leukemia",
          "Acute Myelogenous Leukemia",
          "Myelodysplastic Syndromes",
          "Myelofibrosis",
          "Relapsed Non-Hodgkin Lymphoma",
          "Refractory Non-Hodgkin Lymphoma",
          "Hodgkin Lymphoma",
          "Refractory Hodgkin Lymphoma",
          "Relapsed Chronic Lymphocytic Leukemia",
          "Refractory Chronic Lymphocytic Leukemia",
          "Lymphoid Malignancies",
          "Chronic Myelogenous Leukemia"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Total Body Irradiation",
          "Human Mesenchymal Stromal Cells",
          "hMSC",
          "Cyclophosphamide",
          "Fludarabine",
          "Dimethyl Sulfoxide",
          "DMSO",
          "Cyclosporine",
          "Mycophenolate Mofetil",
          "MMF",
          "Granulocyte- Colony Stimulating Factor",
          "G-CSF",
          "GVHD",
          "Cancer",
          "feasibility"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Early Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "6",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Treatment (intra-osseous UCB with hMSC co-transplant)",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "REDUCED INTENSITY CONDITIONING (RIC):\n\nFlu/Cy/TBI: Patients receive cyclophosphamide IV over 2 hours on day -6 and fludarabine phosphate IV on days -6 to -2 and undergo total-body irradiation on day -1.\n\nFlu/Mel: Patients receive fludarabine daily on days -5 to -2, a single dose of melphalan on day -2, and ATG on day -3 and day-2.\n\nGVHD PROPHYLAXIS: Patients receive cyclosporine PO or IV over 2 hours every 12 hours on beginning on days -5 to 100 with taper beginning on day 100 and mycophenolate mofetil IV or PO BID on days -5 to 100.\n\nTRANSPLANT: Patients undergo a co-transplantation of an intra-osseous umbilical cord blood transplantation and a mesenchymal stem cell transplantation on day 0.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: cyclophosphamide",
                "Drug: fludarabine phosphate",
                "Radiation: total-body irradiation",
                "Drug: cyclosporine",
                "Drug: mycophenolate mofetil",
                "Procedure: umbilical cord blood transplantation",
                "Procedure: mesenchymal stem cell transplantation"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "cyclophosphamide",
            "InterventionDescription": "All patients will receive a single IV dose of 50 mg/kg of cyclophosphamide on day -6",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment (intra-osseous UCB with hMSC co-transplant)"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "CPM",
                "CTX",
                "Cytoxan",
                "Endoxan",
                "Endoxana"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "fludarabine phosphate",
            "InterventionDescription": "Given by IV during prep at 40mg/m2 for 5 days",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment (intra-osseous UCB with hMSC co-transplant)"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "2-F-ara-AMP",
                "Beneflur",
                "Fludara"
              ]
            }
          },
          {
            "InterventionType": "Radiation",
            "InterventionName": "total-body irradiation",
            "InterventionDescription": "Undergo single fraction of reduced intensity conditioning (RIC) regimen of 200 cGy TBI without shielding on day -1",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment (intra-osseous UCB with hMSC co-transplant)"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "TBI"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "cyclosporine",
            "InterventionDescription": "Initiated in patients on the day -5. Cyclosporine will be administered orally or intravenously at 2 mg/kg/dose every 12 hours for 2-hour period. Cyclosporine will continue until day +100",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment (intra-osseous UCB with hMSC co-transplant)"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "ciclosporin",
                "cyclosporin",
                "cyclosporin A",
                "CYSP",
                "Sandimmune"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "mycophenolate mofetil",
            "InterventionDescription": "Given at 1g intravenously or orally twice daily from day -5 to +100, or as clinically indicated.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment (intra-osseous UCB with hMSC co-transplant)"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Cellcept",
                "MMF"
              ]
            }
          },
          {
            "InterventionType": "Procedure",
            "InterventionName": "umbilical cord blood transplantation",
            "InterventionDescription": "Following RIC, on day T+0, dimethylsulphoxide will be removed from the cord blood cells and given as transplant.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment (intra-osseous UCB with hMSC co-transplant)"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "cord blood transplantation",
                "transplantation, umbilical cord blood",
                "UCB transplantation"
              ]
            }
          },
          {
            "InterventionType": "Procedure",
            "InterventionName": "mesenchymal stem cell transplantation",
            "InterventionDescription": "The total dosage of hMSC will be 2x10^6cells/kg (+/-20%).",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment (intra-osseous UCB with hMSC co-transplant)"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "hMSC transplantation"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Number of patients with BM cellularity failure: Measure of feasibility",
            "PrimaryOutcomeDescription": "Primary graft failure is defined by <10% BM cellularity in bone marrow biopsies. Failure in more than 30% of patients will indicate unfeasibility of treatment",
            "PrimaryOutcomeTimeFrame": "42 days after transplant"
          },
          {
            "PrimaryOutcomeMeasure": "Number of patients with ANC failure without evidence of disease: Measure of feasibility",
            "PrimaryOutcomeDescription": "Primary graft failure is defined by <500 ANC cell/ul in bone marrow biopsies. Failure in more than 30% of patients will indicate unfeasibility of treatment",
            "PrimaryOutcomeTimeFrame": "42 days after transplant"
          },
          {
            "PrimaryOutcomeMeasure": "Number of patients with hematopoietic recovery without evidence of donor umbilical cord blood engraftment: Measure of feasibility",
            "PrimaryOutcomeDescription": "Primary graft failure is defined by hematopoietic recovery with <10% donor cell chimerism. Failure in more than 30% of patients will indicate unfeasibility of treatment",
            "PrimaryOutcomeTimeFrame": "42 days after transplant"
          },
          {
            "PrimaryOutcomeMeasure": "Number of patients with hematopoietic recovery without evidence of donor umbilical cord blood engraftment: Measure of feasibility",
            "PrimaryOutcomeDescription": "Primary graft failure is defined by hematopoietic recovery with <40% donor cell chimerism. Failure in more than 30% of patients will indicate unfeasibility of treatment",
            "PrimaryOutcomeTimeFrame": "100 days after transplant"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Incidence of toxicities assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",
            "SecondaryOutcomeDescription": "Descriptive statistics will be used.",
            "SecondaryOutcomeTimeFrame": "Up to 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Rate of neutrophil recovery",
            "SecondaryOutcomeDescription": "The rate of neutrophil recovery and median time of recovery will be estimated using the methods of Kaplan and Meier.",
            "SecondaryOutcomeTimeFrame": "Up to 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Rate of platelet recovery",
            "SecondaryOutcomeDescription": "The rate of platelet recovery and median time of recovery will be estimated using the methods of Kaplan and Meier.",
            "SecondaryOutcomeTimeFrame": "Up to 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Median time of neutrophil recovery",
            "SecondaryOutcomeDescription": "The median time of neutrophil recovery will be estimated using the methods of Kaplan and Meier.",
            "SecondaryOutcomeTimeFrame": "Up to 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Median time of platelet recovery",
            "SecondaryOutcomeDescription": "The median time of platelet recovery will be estimated using the methods of Kaplan and Meier.",
            "SecondaryOutcomeTimeFrame": "Up to 12 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nPatients must have one of the following malignancies:\n\nAcute myelogenous leukemia (AML): high-risk AML including:\n\nAntecedent hematological disease (e.g., myelodysplasia [MDS])\nTreatment-related leukemia\nComplete remission (first complete remission [CR1]) with poor-risk cytogenetics or molecular markers (e.g. fms-related tyrosine kinase 3 [Flt 3] mutation, 11q23, del 5, del 7, complex cytogenetics)\nSecond complete remission (CR2) or third complete remission (CR3)\n\nInduction failure or first relapse with either\n\n≤ 10% blasts in the marrow and/or\n≤ 5% blasts in the peripheral blood\n\nAcute lymphoblastic leukemia (ALL)\n\nHigh-risk CR1 including:\nPoor-risk cytogenetics (e.g., Philadelphia chromosome t(9;22)or 11q23 rearrangements)\nPresence of minimal disease by flow cytometry after 2 or more cycles of chemotherapy\nNo complete remission (CR) within 4 weeks of initial treatment\nInduction failure\n\nCR2 or CR3 with either:\n\n≤ 10% blasts in the marrow and/or\n≤ 5% blasts in the peripheral blood\nMyelodysplastic syndromes (MDS), Intermediate-1 (INT-1), intermediate-2 (INT-2) or high Revised International Prognostic Scoring System (IPSS-R) score that has failed at least 1 first line therapy\n\nMyelofibrosis (MF):\n\nIntermediate-2 or high risk by Dynamic International Prognostic Scoring System (DIPSS)-plus\nMonosomal karyotype\nPresence of inv(3)/i(17q) abnormalities\nOther unfavorable karyotype OR leukocytes ≥40 X 10^9/L AND\nCirculating blasts ≤ 9%\n\nRelapsed or refractory lymphoid malignancies (including non-Hodgkin lymphoma, Hodgkin lymphoma and chronic lymphocytic leukemia) meeting the following criteria:\n\nDisease status: stable disease, partial remission or 2nd and 3rd complete remission\n\nChronic myelogenous leukemia (CML) in second chronic phase after accelerated or blast crisis; blast crisis defined as:\n\nBlast count ≥ 20% in the peripheral blood or bone marrow\nLarge foci of blasts on bone marrow\nPresence of extra-medullary blastic infiltrate (myeloid sarcoma or chloroma)\nRecipients of prior autologous or allogeneic transplant are eligible, as long as at least 3 months have passed since the transplant, and the patient fulfills other eligibility criteria\nEastern Cooperative Oncology Group (ECOG) performance status ≤2\nCandidates for reduced intensity conditioning regimens\nPatients who do not have HLA-matched (defined as matched in HLA A, B, C, and DRB1) related or unrelated donors, those who elect to undergo UCB even if they have a MRD or MUD, or patients who require a UCB either for emergency indications such as primary graft failure.\n\nCord Blood Units available through NMDP with the following minimal criteria:\n\nHLA Match: 4/6 or better match (HLA A, B, DRB1)\nCell dose: Minimum of 2.0x107TNC/kg pre thaw\nConcurrent therapy for extramedullary leukemia or central nervous system (CNS) lymphoma: concurrent therapy or prophylaxis for testicular leukemia, CNS leukemia, and CNS lymphoma including standard intrathecal chemotherapy and/or radiation therapy will be allowed as clinically indicated; such treatment may continue until the planned course is completed; subjects must be in CNS remission at the time of protocol enrollment if there is a history of CNS involvement\nSubjects must have a back-up umbilical cord on the registry in addition to the umbilical cord being used in this study\nSubjects must have the ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\nPatients with inadequate Organ Function as defined by:\n\nCreatinine clearance < 30 ml/min\nBilirubin ≥ 2 x institutional upper limit of normal\nAspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) ≥ 2 x institutional upper limit of normal\nAlanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≥ 2 x institutional upper limit of normal\nCorrected diffusing capacity of the lung for carbon monoxide (DLCOcorr) < 40% normal\nLeft ventricular ejection fraction < 35%\nPatients with uncontrolled inter-current illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\nPregnant or breastfeeding women are excluded from this study",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "75 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Leland Metheny, MD",
            "OverallOfficialAffiliation": "Case Comprehensive Cancer Center",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Case Comprehensive Cancer Center",
            "LocationCity": "Cleveland",
            "LocationState": "Ohio",
            "LocationZip": "44106-5065",
            "LocationCountry": "United States"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000008223",
            "ConditionMeshTerm": "Lymphoma"
          },
          {
            "ConditionMeshId": "D000007938",
            "ConditionMeshTerm": "Leukemia"
          },
          {
            "ConditionMeshId": "D000008228",
            "ConditionMeshTerm": "Lymphoma, Non-Hodgkin"
          },
          {
            "ConditionMeshId": "D000007945",
            "ConditionMeshTerm": "Leukemia, Lymphoid"
          },
          {
            "ConditionMeshId": "D000054198",
            "ConditionMeshTerm": "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
          },
          {
            "ConditionMeshId": "D000015451",
            "ConditionMeshTerm": "Leukemia, Lymphocytic, Chronic, B-Cell"
          },
          {
            "ConditionMeshId": "D000006689",
            "ConditionMeshTerm": "Hodgkin Disease"
          },
          {
            "ConditionMeshId": "D000007951",
            "ConditionMeshTerm": "Leukemia, Myeloid"
          },
          {
            "ConditionMeshId": "D000015464",
            "ConditionMeshTerm": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
          },
          {
            "ConditionMeshId": "D000015470",
            "ConditionMeshTerm": "Leukemia, Myeloid, Acute"
          },
          {
            "ConditionMeshId": "D000009190",
            "ConditionMeshTerm": "Myelodysplastic Syndromes"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000009370",
            "ConditionAncestorTerm": "Neoplasms by Histologic Type"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000008232",
            "ConditionAncestorTerm": "Lymphoproliferative Disorders"
          },
          {
            "ConditionAncestorId": "D000008206",
            "ConditionAncestorTerm": "Lymphatic Diseases"
          },
          {
            "ConditionAncestorId": "D000007160",
            "ConditionAncestorTerm": "Immunoproliferative Disorders"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          },
          {
            "ConditionAncestorId": "D000001855",
            "ConditionAncestorTerm": "Bone Marrow Diseases"
          },
          {
            "ConditionAncestorId": "D000006402",
            "ConditionAncestorTerm": "Hematologic Diseases"
          },
          {
            "ConditionAncestorId": "D000015448",
            "ConditionAncestorTerm": "Leukemia, B-Cell"
          },
          {
            "ConditionAncestorId": "D000009196",
            "ConditionAncestorTerm": "Myeloproliferative Disorders"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M10372",
            "ConditionBrowseLeafName": "Lymphoma",
            "ConditionBrowseLeafAsFound": "Lymphoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M15507",
            "ConditionBrowseLeafName": "Syndrome",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M27465",
            "ConditionBrowseLeafName": "Primary Myelofibrosis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10097",
            "ConditionBrowseLeafName": "Leukemia",
            "ConditionBrowseLeafAsFound": "Leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10107",
            "ConditionBrowseLeafName": "Leukemia, Myeloid",
            "ConditionBrowseLeafAsFound": "Myelogenous Leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M17279",
            "ConditionBrowseLeafName": "Leukemia, Myeloid, Acute",
            "ConditionBrowseLeafAsFound": "Acute Myelogenous Leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10103",
            "ConditionBrowseLeafName": "Leukemia, Lymphoid",
            "ConditionBrowseLeafAsFound": "Lymphocytic Leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M17268",
            "ConditionBrowseLeafName": "Leukemia, Lymphocytic, Chronic, B-Cell",
            "ConditionBrowseLeafAsFound": "Chronic Lymphocytic Leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M26738",
            "ConditionBrowseLeafName": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
            "ConditionBrowseLeafAsFound": "Acute Lymphoblastic Leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M8903",
            "ConditionBrowseLeafName": "Hodgkin Disease",
            "ConditionBrowseLeafAsFound": "Hodgkin Lymphoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11297",
            "ConditionBrowseLeafName": "Myelodysplastic Syndromes",
            "ConditionBrowseLeafAsFound": "Myelodysplastic Syndrome",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M13316",
            "ConditionBrowseLeafName": "Preleukemia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M17275",
            "ConditionBrowseLeafName": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
            "ConditionBrowseLeafAsFound": "Chronic myelogenous leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10374",
            "ConditionBrowseLeafName": "Lymphoma, Non-Hodgkin",
            "ConditionBrowseLeafAsFound": "Non-Hodgkin's Lymphoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11467",
            "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10377",
            "ConditionBrowseLeafName": "Lymphoproliferative Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10355",
            "ConditionBrowseLeafName": "Lymphatic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9358",
            "ConditionBrowseLeafName": "Immunoproliferative Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4286",
            "ConditionBrowseLeafName": "Bone Marrow Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8642",
            "ConditionBrowseLeafName": "Hematologic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M17267",
            "ConditionBrowseLeafName": "Leukemia, B-Cell",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11301",
            "ConditionBrowseLeafName": "Myeloproliferative Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T3543",
            "ConditionBrowseLeafName": "Lymphosarcoma",
            "ConditionBrowseLeafAsFound": "Lymphoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T4705",
            "ConditionBrowseLeafName": "Primary Myelofibrosis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T3995",
            "ConditionBrowseLeafName": "Myeloid Leukemia",
            "ConditionBrowseLeafAsFound": "Myelogenous Leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T182",
            "ConditionBrowseLeafName": "Acute Myeloid Leukemia",
            "ConditionBrowseLeafAsFound": "Acute Myelogenous Leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T188",
            "ConditionBrowseLeafName": "Acute Non Lymphoblastic Leukemia",
            "ConditionBrowseLeafAsFound": "Acute Myelogenous Leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T1308",
            "ConditionBrowseLeafName": "Chronic Lymphocytic Leukemia",
            "ConditionBrowseLeafAsFound": "Chronic Lymphocytic Leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T175",
            "ConditionBrowseLeafName": "Acute Lymphoblastic Leukemia",
            "ConditionBrowseLeafAsFound": "Acute Lymphoblastic Leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T3533",
            "ConditionBrowseLeafName": "Lymphoblastic Lymphoma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T2817",
            "ConditionBrowseLeafName": "Hodgkin Lymphoma",
            "ConditionBrowseLeafAsFound": "Hodgkin Lymphoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T3993",
            "ConditionBrowseLeafName": "Myelodysplastic Syndromes",
            "ConditionBrowseLeafAsFound": "Myelodysplastic Syndrome",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T1309",
            "ConditionBrowseLeafName": "Chronic Myeloid Leukemia",
            "ConditionBrowseLeafAsFound": "Chronic myelogenous leukemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T1311",
            "ConditionBrowseLeafName": "Chronic Myeloproliferative Disorders",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC15",
            "ConditionBrowseBranchName": "Blood and Lymph Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "D000016572",
            "InterventionMeshTerm": "Cyclosporine"
          },
          {
            "InterventionMeshId": "D000009173",
            "InterventionMeshTerm": "Mycophenolic Acid"
          },
          {
            "InterventionMeshId": "D000003520",
            "InterventionMeshTerm": "Cyclophosphamide"
          },
          {
            "InterventionMeshId": "C000024352",
            "InterventionMeshTerm": "Fludarabine"
          },
          {
            "InterventionMeshId": "C000042382",
            "InterventionMeshTerm": "Fludarabine phosphate"
          },
          {
            "InterventionMeshId": "D000003524",
            "InterventionMeshTerm": "Cyclosporins"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000007166",
            "InterventionAncestorTerm": "Immunosuppressive Agents"
          },
          {
            "InterventionAncestorId": "D000007155",
            "InterventionAncestorTerm": "Immunologic Factors"
          },
          {
            "InterventionAncestorId": "D000045505",
            "InterventionAncestorTerm": "Physiological Effects of Drugs"
          },
          {
            "InterventionAncestorId": "D000018501",
            "InterventionAncestorTerm": "Antirheumatic Agents"
          },
          {
            "InterventionAncestorId": "D000018906",
            "InterventionAncestorTerm": "Antineoplastic Agents, Alkylating"
          },
          {
            "InterventionAncestorId": "D000000477",
            "InterventionAncestorTerm": "Alkylating Agents"
          },
          {
            "InterventionAncestorId": "D000045504",
            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
          },
          {
            "InterventionAncestorId": "D000000970",
            "InterventionAncestorTerm": "Antineoplastic Agents"
          },
          {
            "InterventionAncestorId": "D000019653",
            "InterventionAncestorTerm": "Myeloablative Agonists"
          },
          {
            "InterventionAncestorId": "D000000964",
            "InterventionAncestorTerm": "Antimetabolites, Antineoplastic"
          },
          {
            "InterventionAncestorId": "D000000963",
            "InterventionAncestorTerm": "Antimetabolites"
          },
          {
            "InterventionAncestorId": "D000004791",
            "InterventionAncestorTerm": "Enzyme Inhibitors"
          },
          {
            "InterventionAncestorId": "D000000935",
            "InterventionAncestorTerm": "Antifungal Agents"
          },
          {
            "InterventionAncestorId": "D000000890",
            "InterventionAncestorTerm": "Anti-Infective Agents"
          },
          {
            "InterventionAncestorId": "D000003879",
            "InterventionAncestorTerm": "Dermatologic Agents"
          },
          {
            "InterventionAncestorId": "D000065095",
            "InterventionAncestorTerm": "Calcineurin Inhibitors"
          },
          {
            "InterventionAncestorId": "D000000903",
            "InterventionAncestorTerm": "Antibiotics, Antineoplastic"
          },
          {
            "InterventionAncestorId": "D000000904",
            "InterventionAncestorTerm": "Antibiotics, Antitubercular"
          },
          {
            "InterventionAncestorId": "D000000995",
            "InterventionAncestorTerm": "Antitubercular Agents"
          },
          {
            "InterventionAncestorId": "D000000900",
            "InterventionAncestorTerm": "Anti-Bacterial Agents"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M5879",
            "InterventionBrowseLeafName": "Cyclophosphamide",
            "InterventionBrowseLeafAsFound": "Months",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M11280",
            "InterventionBrowseLeafName": "Mycophenolic Acid",
            "InterventionBrowseLeafAsFound": "Plasma",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M18113",
            "InterventionBrowseLeafName": "Cyclosporine",
            "InterventionBrowseLeafAsFound": "2 weeks",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M5882",
            "InterventionBrowseLeafName": "Cyclosporins",
            "InterventionBrowseLeafAsFound": "2 weeks",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M283219",
            "InterventionBrowseLeafName": "Fludarabine",
            "InterventionBrowseLeafAsFound": "Medical",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M244297",
            "InterventionBrowseLeafName": "Sargramostim",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M225481",
            "InterventionBrowseLeafName": "Fludarabine phosphate",
            "InterventionBrowseLeafAsFound": "Problems",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M10693",
            "InterventionBrowseLeafName": "Melphalan",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M6457",
            "InterventionBrowseLeafName": "Dimethyl Sulfoxide",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M1945",
            "InterventionBrowseLeafName": "Lenograstim",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9364",
            "InterventionBrowseLeafName": "Immunosuppressive Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9353",
            "InterventionBrowseLeafName": "Immunologic Factors",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M19757",
            "InterventionBrowseLeafName": "Antirheumatic Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M20095",
            "InterventionBrowseLeafName": "Antineoplastic Agents, Alkylating",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M2972",
            "InterventionBrowseLeafName": "Alkylating Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3433",
            "InterventionBrowseLeafName": "Antimetabolites",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M5404",
            "InterventionBrowseLeafName": "Clotrimazole",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M10948",
            "InterventionBrowseLeafName": "Miconazole",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3406",
            "InterventionBrowseLeafName": "Antifungal Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3366",
            "InterventionBrowseLeafName": "Anti-Infective Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M6226",
            "InterventionBrowseLeafName": "Dermatologic Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M29605",
            "InterventionBrowseLeafName": "Calcineurin Inhibitors",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3374",
            "InterventionBrowseLeafName": "Anti-Bacterial Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3376",
            "InterventionBrowseLeafName": "Antibiotics, Antitubercular",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3463",
            "InterventionBrowseLeafName": "Antitubercular Agents",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "ANeo",
            "InterventionBrowseBranchName": "Antineoplastic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "ARhu",
            "InterventionBrowseBranchName": "Antirheumatic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "Infe",
            "InterventionBrowseBranchName": "Anti-Infective Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "Derm",
            "InterventionBrowseBranchName": "Dermatologic Agents"
          }
        ]
      }
    }
  }
}